RBM8A: A Promising RNA-Based Biomarker and Potential Drug Target

Target Name: RBM8A

NCBI ID: G9939

RBM8A

RBM8A: A Promising RNA-Based Biomarker and Potential Drug Target

The study of RNA-based biomarkers has gained significant attention in recent years due to their potential as therapeutic targets or for the diagnosis and monitoring of various diseases. One of the promising RNA-based biomarkers is RBM8A (BOV-1A), which has been shown to be involved in a variety of biological processes and has the potential to serve as a drug target or biomarker. In this article, we will explore the biology and potential applications of RBM8A and its potential as a drug target.

The biology of RBM8A

RBM8A is a non-coding RNA molecule that has been shown to play a role in various cellular processes, including cell adhesion, migration, and the regulation of gene expression. It is a member of the BOV family of RNA molecules, which are characterized by their ability to self-cleave and have been shown to play a role in various cellular processes.

One of the most interesting features of RBM8A is its ability to interact with the protein S100, which is a known regulator of cell adhesion and migration. S100 is known to play a role in the regulation of cell adhesion by interacting with various adhesion molecules, including cadherins and integrins. By interacting with S100, RBM8A has been shown to regulate the formation and maintenance of tight junctions, which are a type of cell-cell adhesion that is critical for the proper functioning of various tissues.

In addition to its role in cell adhesion and migration, RBM8A has also been shown to play a role in the regulation of gene expression. It has been shown to interact with the protein component BISC/NEDD8, which is a known regulator of gene expression. . This interaction between RBM8A and BISC/NEDD8 has been shown to play a role in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

Potential applications of RBM8A as a drug target

The potential applications of RBM8A as a drug target are vast and varied. One of the most promising applications is its potential as a target for cancer therapies. Cancer is a leading cause of death worldwide, and there is a significant need for new and effective therapies for the treatment of this disease. RBM8A has been shown to play a role in the regulation of cell growth and apoptosis, which are critical processes for the development and progression of cancer. Therefore, RBM8A may be a useful target for cancer therapies that aim to inhibit these processes.

In addition to its potential as a cancer therapeutic, RBM8A may also be a useful target for other diseases. For example, RBM8A has been shown to play a role in the regulation of cell migration, which is critical for the development of various diseases, including neurodegenerative disorders and cardiovascular diseases. Therefore, RBM8A may be a useful target for therapies that aim to treat these diseases.

Potential applications of RBM8A as a biomarker

RBM8A may also be a useful biomarker for a variety of diseases. Its ability to interact with S100 and BISC/NEDD8 has been shown to play a role in the regulation of cellular processes, which may be relevant to the diagnosis and monitoring of various diseases.

For example, RBM8A has been shown to play a role in the regulation of cell adhesion, which is a critical process for the development and maintenance of various tissues. Therefore, RBM8A may be a useful biomarker for the diagnosis and monitoring of diseases that are characterized by disrupted cell adhesion, such as cancer, neurodegenerative disorders, and cardiovascular diseases.

In addition, RBM8A has also been shown to play a role in

Protein Name: RNA Binding Motif Protein 8A

Functions: Required for pre-mRNA splicing as component of the spliceosome (PubMed:28502770, PubMed:29301961). Core component of the splicing-dependent multiprotein exon junction complex (EJC) deposited at splice junctions on mRNAs. The EJC is a dynamic structure consisting of core proteins and several peripheral nuclear and cytoplasmic associated factors that join the complex only transiently either during EJC assembly or during subsequent mRNA metabolism. The EJC marks the position of the exon-exon junction in the mature mRNA for the gene expression machinery and the core components remain bound to spliced mRNAs throughout all stages of mRNA metabolism thereby influencing downstream processes including nuclear mRNA export, subcellular mRNA localization, translation efficiency and nonsense-mediated mRNA decay (NMD). The MAGOH-RBM8A heterodimer inhibits the ATPase activity of EIF4A3, thereby trapping the ATP-bound EJC core onto spliced mRNA in a stable conformation. The MAGOH-RBM8A heterodimer interacts with the EJC key regulator PYM1 leading to EJC disassembly in the cytoplasm and translation enhancement of EJC-bearing spliced mRNAs by recruiting them to the ribosomal 48S preinitiation complex. Its removal from cytoplasmic mRNAs requires translation initiation from EJC-bearing spliced mRNAs. Associates preferentially with mRNAs produced by splicing. Does not interact with pre-mRNAs, introns, or mRNAs produced from intronless cDNAs. Associates with both nuclear mRNAs and newly exported cytoplasmic mRNAs. The MAGOH-RBM8A heterodimer is a component of the nonsense mediated decay (NMD) pathway. Involved in the splicing modulation of BCL2L1/Bcl-X (and probably other apoptotic genes); specifically inhibits formation of proapoptotic isoforms such as Bcl-X(S); the function is different from the established EJC assembly

The "RBM8A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBM8A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets